Literature DB >> 19628331

HPV-induced oropharyngeal cancer, immune response and response to therapy.

Ha Linh Vu1, Andrew G Sikora, Shibo Fu, Johnny Kao.   

Abstract

Approximately 25% of head and neck squamous cell carcinoma (HNSCC) worldwide are associated with high-risk human papillomaviruses (HPV). HPV-positive HNSCCs have a more favorable outcome and greater response to therapy. While chronic HPV infection allows for the evolution of immune evasion mechanisms, viral antigens can still elicit an immune response. Moreover, a robust lymphocytic response is associated with better prognosis in a variety of tumor types including head and neck cancer. This article outlines several mechanisms whereby the observed improved response of HPV-positive tumors to radiotherapy may be related to enhancement of the immune response following radiotherapy. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19628331     DOI： 10.1016/j.canlet.2009.06.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  31 in total

1.  Implications of the oropharyngeal cancer epidemic.

Authors:  Edmund A Mroz; Arlene A Forastiere; James W Rocco
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

2.  Trends in incidence of oral and pharyngeal carcinoma in Florida: 1981-2008.

Authors:  Susan P McGorray; Yi Guo; Henrietta Logan
Journal:  J Public Health Dent       Date:  2011-09-19       Impact factor: 1.821

3.  The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model.

Authors:  Stephen Tuttle; Lauren Hertan; Natalie Daurio; Sarah Porter; Charanya Kaushick; Daqing Li; Shunsuke Myamoto; Alex Lin; Bert W O'Malley; Constantinos Koumenis
Journal:  Cancer Biol Ther       Date:  2012-05-01       Impact factor: 4.742

4.  Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy.

Authors:  Johnny Kao; K H Vincent Lau; Charles C L Tong; Chien-Ting Chen
Journal:  Exp Ther Med       Date:  2012-02-23       Impact factor: 2.447

5.  Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer.

Authors:  Derrick Wansom; Emily Light; Dafydd Thomas; Francis Worden; Mark Prince; Susan Urba; Douglas Chepeha; Bhavna Kumar; Kitrina Cordell; Avraham Eisbruch; Jeremy Taylor; Jeffrey Moyer; Carol Bradford; Nisha D'Silva; Thomas Carey; Jonathan McHugh; Gregory Wolf
Journal:  Laryngoscope       Date:  2012-01       Impact factor: 3.325

Review 6.  Biology of human papillomavirus-related oropharyngeal cancer.

Authors:  Jason D Howard; Christine H Chung
Journal:  Semin Radiat Oncol       Date:  2012-07       Impact factor: 5.934

Review 7.  Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer.

Authors:  John P Finnigan; Andrew G Sikora
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

Review 8.  Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.

Authors:  Charles C L Tong; Johnny Kao; Andrew G Sikora
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 9.  Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment.

Authors:  Juliana Bonilla-Velez; Edmund A Mroz; Rebecca J Hammon; James W Rocco
Journal:  Otolaryngol Clin North Am       Date:  2013-06-27       Impact factor: 3.346

10.  Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Authors:  Daniel W Bowles; Jennifer R Diamond; Elaine T Lam; Colin D Weekes; David P Astling; Ryan T Anderson; Stephen Leong; Lia Gore; Marileila Varella-Garcia; Brian W Vogler; Stephen B Keysar; Elizabeth Freas; Dara L Aisner; Chen Ren; Aik-Chook Tan; Francois Wilhelm; Manoj Maniar; S Gail Eckhardt; Wells A Messersmith; Antonio Jimeno
Journal:  Clin Cancer Res       Date:  2014-02-03       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.